Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling (Q27853157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Paul A VanderLaan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Susan E Costa Jorge

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Daniel B Costa

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Xiuning Le

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mark S Huberman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Deepa Rangachari

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Antonio R Lucena-Araujo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Susumu S Kobayashi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sohail Balasubramanian

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jie He

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Yakov Chudnovsky

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Vincent A Miller

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Siraj M Ali

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

September 2015

0 references

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

e105-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

10 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

20 March 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Management and future directions in non-small cell lung cancer with known activating mutations

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4418215

10.1016/J.CLLC.2015.03.002

27 November 2018

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25922291%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2 references